Jul. 21 at 1:55 PM
$NNVC: Nano (small) Viri (virus) Cides (killers), a clinical stage leader ---- developing antiviral drugs ---- that viruses cannot escape, ---- announces that it has received ... National Ethics Committee approval ---- for a Phase II Clinical Trial ---- of NV-387 Oral Gummies ---- as a Treatment for ---- the Bundibugyo Ebolavirus ----in the Democratic Republic of Congo (DRC).
We expect the Clinical Trial Application to ACOREP, the regulatory agency in DRC, WILL BE APPROVED THIS WEEK, because most of the documents are identical to those submitted for Mpox, which has already been given full authorization by ACOREP to conduct that trial.
Any of you investors that have not fully bought a meaningful position in the common stock should do so ASAP, considering the virus has already killed over 1000 infected people.
